SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases

globe_newswire · 2026-10-22

$SCYX

JERSEY CITY, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”, or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced topline results from its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of the intravenous (IV) formulation of SCY-247, its second-generation triterpenoid (fungerp) antifungal candidate. SCY-247 is under development in both oral an

Sector coverage: Healthcare · Drug Manufacturers - Specialty & Generic

Read the original at globe_newswire ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.